ESPR has 36-month beta value of 0.91. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ESPR is 194.19M, and currently, short sellers hold a 18.22% ratio of that float. The average trading volume of ESPR on November 05, 2024 was 3.55M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ESPR) stock’s latest price update
The stock price of Esperion Therapeutics Inc (NASDAQ: ESPR) has dropped by -1.48 compared to previous close of 2.03. Despite this, the company has seen a fall of -6.10% in its stock price over the last five trading days. globenewswire.com reported 2024-11-04 that ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET.
ESPR’s Market Performance
ESPR’s stock has fallen by -6.10% in the past week, with a monthly drop of -7.41% and a quarterly drop of -0.50%. The volatility ratio for the week is 4.53% while the volatility levels for the last 30 days are 5.78% for Esperion Therapeutics Inc. The simple moving average for the past 20 days is -2.82% for ESPR’s stock, with a -9.59% simple moving average for the past 200 days.
Analysts’ Opinion of ESPR
Many brokerage firms have already submitted their reports for ESPR stocks, with BofA Securities repeating the rating for ESPR by listing it as a “Underperform.” The predicted price for ESPR in the upcoming period, according to BofA Securities is $2.50 based on the research report published on June 20, 2024 of the current year 2024.
ESPR Trading at 6.47% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.18% of loss for the given period.
Volatility was left at 5.78%, however, over the last 30 days, the volatility rate increased by 4.53%, as shares sank -1.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.99% upper at present.
During the last 5 trading sessions, ESPR fell by -6.10%, which changed the moving average for the period of 200-days by -0.99% in comparison to the 20-day moving average, which settled at $2.06. In addition, Esperion Therapeutics Inc saw -33.11% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Warren Eric, who sale 107 shares at the price of $2.12 back on Oct 17 ’24. After this action, Warren Eric now owns 162,552 shares of Esperion Therapeutics Inc, valued at $227 using the latest closing price.
Warren Eric, the Officer of Esperion Therapeutics Inc, proposed sale 107 shares at $2.12 during a trade that took place back on Oct 17 ’24, which means that Warren Eric is holding shares at $227 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.82 for the gross margin
The net margin for Esperion Therapeutics Inc stands at -0.35. The total capital return value is set at 0.03.
Based on Esperion Therapeutics Inc (ESPR), the company’s capital structure generated 2.65 points at debt to capital in total, while cash flow to debt ratio is standing at -0.02. The debt to equity ratio resting at -1.61. The interest coverage ratio of the stock is -20.7.
Currently, EBITDA for the company is -155.4 million with net debt to EBITDA at 74.0. When we switch over and look at the enterprise to sales, we see a ratio of 2.74. The receivables turnover for the company is 4.6for trailing twelve months and the total asset turnover is 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.97.
Conclusion
To put it simply, Esperion Therapeutics Inc (ESPR) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
